GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (STU:YB4P) » Definitions » Net Change in Cash

Savara (STU:YB4P) Net Change in Cash : €-15.77 Mil (TTM As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Savara Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Savara's Net Change in Cash for the three months ended in Mar. 2024 was €-9.02 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was €-15.77 Mil.


Savara Net Change in Cash Historical Data

The historical data trend for Savara's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savara Net Change in Cash Chart

Savara Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.95 -22.13 9.85 17.08 -23.40

Savara Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.92 -10.37 4.63 -1.01 -9.02

Savara Net Change in Cash Calculation

Savara's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Savara's Net Change in Cash for the quarter that ended in Mar. 2024


Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-15.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Savara Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Savara's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.


Savara (STU:YB4P) Business Description

Traded in Other Exchanges
Address
6836 Bee Cave Road, Building I, Suite 205, Austin, TX, USA, 78746
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Savara (STU:YB4P) Headlines

No Headlines